



# JOURNAL OF REPRODUCTIVE IMMUNOLOGY

The International Journal for Experimental and Clinical Reproductive Immunobiology

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Audience</b>	<b>p.2</b>
●	<b>Impact Factor</b>	<b>p.2</b>
●	<b>Abstracting and Indexing</b>	<b>p.2</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.4</b>



ISSN: 0165-0378

### DESCRIPTION

Affiliated with the [European Society of Reproductive Immunology](#) and with the International Society for Immunology of Reproductionthe [International Society for Immunology of Reproduction](#)

The aim of the *Journal of Reproductive Immunology* is to provide the critical forum for the dissemination of results from high quality research in all aspects of experimental, animal and clinical **reproductive immunobiology**.

This encompasses normal and pathological processes of:

- \* Male and Female **Reproductive Tracts**
- \* **Gametogenesis** and **Embryogenesis**
- \* **Implantation** and **Placental Development**
- \* **Gestation** and **Parturition**
- \* **Mammary Gland** and **Lactation**.

Including:

- \* Infectious disease, including STDs
- \* Inflammation
- \* Autoimmunity
- \* Mucosal Immunology
- \* Cytokines and Other Immune Mediators
- \* Immunoendocrinology
- \* Reproductive Immunotherapies
- \* Immunogenetics
- \* Developmental Immunology
- \* Immunology of Reproductive Cancers
- \* Application of Immunological Techniques in Eluciation of Reproductive Processes or Dysfunction.

The international character of the Journal is reflected in the breadth of its [Editorial Board](#) and commitment to publish new and outstanding studies in different aspects of reproductive immunobiology from all five continents. Within the Journal, the Editors wish to bridge the gap between basic and clinical studies in all subareas of research relevant to reproductive immunobiology.

## AUDIENCE

---

Immunologists, Obstetricians and Gynaecologists, Reproductive Biologists

## IMPACT FACTOR

---

2013: 2.373 © Thomson Reuters Journal Citation Reports 2014

## ABSTRACTING AND INDEXING

---

SciFinder  
Current Contents/Life Sciences  
MEDLINE®  
EMBASE  
Pascal et Francis (INST-CNRS)  
Reproduction Research  
Science Citation Index  
BIOSIS Previews  
Scopus  
Science Citation Index Expanded

## EDITORIAL BOARD

---

### *Chief Editors*

**Petra Arck**, University Medical Center Hamburg-Eppendorf, Dept. of Obstetrics & Fetal Medicine, Martinistraße 52, 20246 Hamburg, Germany, Fax: +49 40 7410 40181

**Shigeru Saito**, University of Toyama, Dept. of Obstetrics & Gynecology, 2630 Sugitani, 930-0194 Toyama, Japan, Fax: +81 76 434 5036

**D. Ware Branch**, University of Utah Hospital, Dept. of Obstetrics & Gynecology, 50 N Medical Drive, Salt Lake City, UT 84132, USA, Fax: +1 801 585 2594

### *Assistant Editor*

**M.E. Solano**, Hamburg, Germany

### *Section Editor (Animal Sciences)*

**G. Entrican**, Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Edinburgh, EH26 0PZ, UK, Fax: +44 131 445 6235

### *Section Editor (Basic Immunology)*

**M.P. Hedger**, Monash University, Inst. of Reproduction & Development, 246 Clayton Road, Clayton, VIC 3168, Australia, Fax: +61 3 9594 7416

### *Section Editor (Clinical Studies)*

**D.J. Dudley**, University of Texas Health Sciences Center, Dept. of Obstetrics and Gynecology, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA, Fax: +1 210 567 3013

### *Editorial Board*

**K. Aagaard**, Salt Lake City, Utah, USA

**V.M. Abrahams**, New Haven, Connecticut, USA

**K.M. Adams**, Seattle, Washington, USA

**K.W. Beagley**, Kelvin Grove, Queensland, Australia

**S.M. Blois**, Berlin, Germany

**L.W. Chamley**, Auckland, New Zealand

**G. Chaouat**, Clamart, France

**O.B. Christiansen**, Copenhagen, Denmark

**H.O. Critchley**, Edinburgh, Scotland, UK

**S. Daher**, Sao Paulo, Brazil

**E. Dimitriadis**, Clayton, Victoria, Australia

**A. Erlebacher**, New York, New York, USA

**L. Fainboim**, Buenos Aires, Argentina

**H. Fujiwara**, Kanazawa, Japan

**A. Fukui**, Hirosaki, Japan

**J.V. Garcia-Martinez**, Chapel Hill, North Carolina, USA  
**C. Graham**, Kingston, Ontario, Canada  
**S.K. Gupta**, New Delhi, India  
**T. Kimura**, Osaka, Japan  
**K. Koga**, Bunkyo-Ku, Japan  
**M. Kurpisz**, Poznan, Poland  
**J.Y. Kwak-Kim**, Vernon Hills, Illinois, USA  
**G.E. Lash**, Newcastle upon Tyne, UK  
**P. Le Bouteiller**, Toulouse, France  
**N. Ledée**, Clamart, France  
**Y. Lin**, Shanghai, China  
**U. Markert**, Jena, Germany  
**A. Meinhardt**, Giessen, Germany  
**J.L. Pate**, University Park, Pennsylvania, USA  
**M.G. Petroff**, Kansas City, Kansas, USA  
**S. Pierangeli**, Galveston, Texas, USA  
**S. Robertson**, Adelaide, South Australia, Australia  
**S.A. Scherjon**, Groningen, The Netherlands  
**P. Sedlmayr**, Graz, Austria  
**J. Szekeres-Bartho**, Pécs, Hungary  
**D.S. Torry**, Carbondale, Illinois, USA  
**H. Wang**, Beijing, China  
**C.R. Wira**, Lebanon, New Hampshire, USA

***Editors Emeritus***

**J.S. Hunt**, Kansas City, Kansas, USA  
**P.M. Johnson**, Liverpool, UK  
**S. Robertson**, Adelaide, South Australia, Australia

## GUIDE FOR AUTHORS

---

### INTRODUCTION

The aim of the *Journal of Reproductive Immunology* is to provide the critical forum for the dissemination of results from high quality research in all aspects of experimental, animal and clinical reproductive immunobiology.

This encompasses normal and pathological processes of:

Male and Female Reproductive Tracts Gametogenesis and Embryogenesis Implantation and Placental Development Gestation and Parturition Mammary Gland and Lactation

Including:

Infectious disease, including STDs Inflammation Autoimmunity Mucosal Immunology Cytokines and Other Immune Mediators Immunoendocrinology Reproductive Immunotherapies Immunogenetics Developmental Immunology Immunology of Reproductive Cancers Application of Immunological Techniques to Elucidate Reproductive Processes or Dysfunction

The international character of the Journal is reflected in the breadth of its Editorial Board and commitment to publish new and outstanding studies in different aspects of reproductive immunobiology from all five continents. The Journal scope spans basic science, animal and clinical studies in all subareas of research relevant to reproductive immunobiology.

### *Types of papers*

*Original articles:* a full-length report of original basic or clinical investigation (generally not exceeding 3000 words or 45 references with up to 4 figures and 4 tables). An unstructured abstract of no more than 250 words stating objectives, study design, main outcome measures, results and conclusions is required. The text should be structured as follows: Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figure Legends. We offer fast-track peer review and publication of randomized controlled trials that we judge of importance to practice or research (see Fast-track publication). We invite submission of all clinical trials, whether Phase I, II, or III.

Submission of randomized controlled trials requires inclusion of a checklist and flowchart in accordance with the CONSORT guidelines and the registration number of the trial and the name of the trial registry. Studies of diagnostic accuracy must be reported according to STARD guidelines. Observational studies (cohort, case-control, or cross-sectional designs) must be reported according to the STROBE statement (see also <http://www.strobe-statement.org>).

*Short communications* should not exceed 1,500 words with no more than one table or illustration and ten references. An unstructured abstract of no more than 100 words is required. The text should be structured as follows: Abstract, Introduction, Materials and Methods, Results and Discussion (combined), Acknowledgements, References, Tables, Figure Legends.

*Review articles:* a comprehensive review providing a synthesis and interpretation of prior publications relating to an important research or clinical subject (generally not exceeding 5,000 words, 2-4 figures and/or tables and 50-60 references). An unstructured abstract of no more than 250 words is required. The Introduction should indicate why the topic is important and should state the specific objective(s) of the review. The Conclusion should include the clinical implications and observations regarding the need for additional research. Systematic reviews should follow the PRISMA guidelines. Meta-analysis of observational studies should follow the MOOSE guidelines.

Further information can be obtained from the EQUATOR web site: <http://www.equator-network.org/resource-centre/library-of-health-research-reporting/reporting-guidelines>

*Opinion Papers:* are welcomed, but should include new data or concepts and generally not exceed 1,500 words and ten references.

*Letters to the Editor:* a question or challenge to a recently published article. Letters must be received within 6 weeks of publication of the article to which they refer and should be no longer than 500 words.

### *Contact details for submission*

Submission of manuscripts proceeds entirely online at <http://ees.elsevier.com/jri/>.

## **BEFORE YOU BEGIN**

### **Ethics in publishing**

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

### **Human and animal rights**

If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans <http://www.wma.net/en/30publications/10policies/b3/index.html>; EU Directive 2010/63/EU for animal experiments [http://ec.europa.eu/environment/chemicals/lab\\_animals/legislation\\_en.htm](http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm); Uniform Requirements for manuscripts submitted to Biomedical journals <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

### **Conflict of interest**

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <http://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: [http://help.elsevier.com/app/answers/detail/a\\_id/286/p/7923](http://help.elsevier.com/app/answers/detail/a_id/286/p/7923).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

### **Contributors**

Submission of multi-authored manuscripts to this journal requires the consent of each author and all must sign the covering letter. All authors, and all contributors (including medical writers and editors) must specify their individual contributions and any conflicts of interest in statements to be listed in the "Comments" field in EES (Elsevier Editorial System). The following format is suggested: "I declare that I participated in the study by (here list the specific contributions made to the study) and that I have seen and approved the final version. I have the following conflicts of interest" (list here all relevant conflicts).

### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

## Article transfer service

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information about this can be found here: <http://www.elsevier.com/authors/article-transfer-service>.

## Copyright

This journal offers authors a choice in publishing their research: Open access and Subscription.

### *For subscription articles*

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <http://www.elsevier.com/copyright>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

### *For open access articles*

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <http://www.elsevier.com/OAauthoragreement>). Permitted reuse of open access articles is determined by the author's choice of user license (see <http://www.elsevier.com/openaccesslicenses>).

## Retained author rights

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see <http://www.elsevier.com/journal-authors/author-rights-and-responsibilities>.

Open access articles please see <http://www.elsevier.com/OAauthoragreement>.

## Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

## Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

## Open access

This journal offers authors a choice in publishing their research:

### **Open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (<http://www.elsevier.com/access>)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA):** for non-commercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND):** for non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Elsevier has established agreements with funding bodies, <http://www.elsevier.com/fundingbodies>. This ensures authors can comply with funding body open access requirements, including specific user licenses, such as CC BY. Some authors may also be reimbursed for associated publication fees. If you need to comply with your funding body policy, you can apply for the CC BY license after your manuscript is accepted for publication.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access. Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The open access publication fee for this journal is **\$2500**, excluding taxes. Learn more about Elsevier's pricing policy: <http://www.elsevier.com/openaccesspricing>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

### **Informed consent and patient details**

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the *Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals*, <http://www.elsevier.com/patient-consent-policy>. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

### **Referees**

To expedite the review process Authors are required to provide the editorial office with the names and email addresses of 4 potential referees that are able to competently review the article submitted for possible publication. The referees must not be associated with or involved with the article in any way or be from the same institution as the author(s) of the article.

## PREPARATION

### *Use of word processing software*

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### *LaTeX*

You are recommended to use the Elsevier article class *elsarticle.cls* (<http://www.ctan.org/tex-archive/macros/latex/contrib/elsarticle>) to prepare your manuscript and BibTeX (<http://www.bibtex.org>) to generate your bibliography.

For detailed submission instructions, templates and other information on LaTeX, see <http://www.elsevier.com/latex>.

### *Article structure*

#### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

#### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

The Methods section should describe the research methodology in sufficient detail that others could reasonably be expected to be able to duplicate the work. However, if the methodology has been previously published, the appropriate reference should be cited, and a full description is not required. Methods of statistical analysis should be identified and, when appropriate, the basis for their selection stated. Statistical software programs used should be cited in the text. *P* values should be expressed to no more than three decimal places. Reports in which statistical difference is lacking must provide some indication of the study's power to detect such differences, and this information must be included in the abstract.

### *Results*

The Results section should present the findings in appropriate detail, but as concisely as possible. Tables and figures may be used, but duplication between text and tables or figures is to be avoided.

### *Discussion*

The Discussion section should be used to critically appraise the implications of the findings and to compare them with those of other studies. Repetition of the results section should be avoided. The last paragraph of the discussion should state the main conclusions of the study.

#### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### *Essential title page information*

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.



• **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

• **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**

• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

### **Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See <http://www.elsevier.com/graphicalabstracts> for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images and in accordance with all technical requirements: [Illustration Service](#).

### **Highlights**

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <http://www.elsevier.com/highlights> for examples.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords while avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes

### **Abbreviations**

Abbreviations other than those listed below must be defined in full in a footnote to be placed on the first page of the article.

Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

[Please click here for a list of journal approved abbreviations.](#)

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

## Nomenclature and units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to consult IUPAC: Nomenclature of Organic Chemistry: <http://www.iupac.org/> for further information.

## Database linking

Elsevier encourages authors to connect articles with external databases, giving their readers one-click access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See <http://www.elsevier.com/databaselinking> for more information and a full list of supported databases.

## Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

## Artwork

### Electronic artwork

#### General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the printed version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

#### Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

#### Preparing artwork for publication in JRI

Click [here](#) how to submit your artwork.

#### Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

Please note: Because of technical complications that can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

### **Figure legends**

Ensure that each figure has a legend. Supply legends separately as the final section of the manuscript text file, not attached to the figure, numbered in Arabic numerals to match the figure. A legend should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but define all symbols and abbreviations used (other than standard abbreviations listed above).

### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

### **References**

Authors are responsible for the accuracy of references. The 'Harvard' style is used. References appearing for the first time in a table or figure should be cited in the text where the table or figure is mentioned. References cited must have been published in peer-reviewed publications.

#### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

#### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### **Reference style**

In the text, references should be cited by author and year (Harvard System). More than one paper from the same author in the same year must be identified separately by the letters a, b, c, etc. placed after the year of publication. In the text, when referring to a work by more than two authors, the name of the first author should be given followed by et al. In the reference list, citation of periodical, book or multi-author book articles should comply with the following examples:

**Text:** All citations in the text should refer to:

1. *Single author:* the author's name (without initials, unless there is ambiguity) and the year of publication;
2. *Two authors:* both authors' names and the year of publication;
3. *Three or more authors:* first author's name followed by "et al." and the year of publication.

Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.

Examples: "as demonstrated (Allan, 1996a, 1996b, 1999; Allan and Jones, 1995). Kramer et al. (2000) have recently shown ...."

**List:** References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters "a", "b", "c", etc., placed after the year of publication.

Examples:

Reference to a journal publication:

Saito, S., Sasaki, Y., Sakai, M., 2005. CD4+CD25high regulatory T cells in human pregnancy. *J. Reprod. Immunol.* 65, 111-120.

Reference to a book:

Anderson, D.J., 1996. Interaction between male genital tract infection, immunity and infertility. In: Bronson, R.A. et al. (Eds.), *Reproductive Immunology*. Blackwell, Cambridge, MA, pp. 532-539.

Reference to a chapter in an edited book:

Cobley, U.T. et al., 2005. *Reproductive Immunobiology*. Widdicombe Fair Press, London.

Note that for more than 6 authors the first 6 should be listed followed by "et al." For further details you are referred to "Uniform Requirements for Manuscripts submitted to Biomedical Journals" (*J Am Med Assoc* 1997;277:927-934), see also [http://www.nlm.nih.gov/tsd/serials/terms\\_cond.html](http://www.nlm.nih.gov/tsd/serials/terms_cond.html)

*Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

### **Video data**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <http://www.elsevier.com/audioslides>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

### **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.
- For reproduction in black-and-white, please supply black-and-white versions of the figures for printing purposes.

For any further information please visit our customer support site at <http://support.elsevier.com>.

## **AFTER ACCEPTANCE**

### ***Use of the Digital Object Identifier***

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### ***Online proof correction***

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### ***Offprints***

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](http://www.sciencedirect.com). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

## **AUTHOR INQUIRIES**

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>